BRIDGEWAY CAPITAL MANAGEMENT, LLC

Position in DSGN — Design Therapeutics, Inc.

CIK 1107261 HOUSTON, TX

Position in DSGN

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$390,690

-$162,590 QoQ

Shares Held

27,000

-48.1% QoQ

Ownership

0.043%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#73

of 136 holders

Holding Since

Sep 2023

12 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

BRIDGEWAY CAPITAL MANAGEMENT, LLC holds $87,985,615 across 108 Biotechnology names. DSGN ranks #48 (0.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	GLUE	Monte Rosa Therapeutics, Inc.	552,566	$13,372,097
2	INVA	Innoviva, Inc.	350,253	$7,954,245
3	PBYI	Puma Biotechnology, Inc.	791,616	$6,420,005
4	RIGL	Rigel Pharmaceuticals Inc	124,184	$4,858,078
5	EXEL	Exelixis, Inc.	66,100	$3,596,501
6	CRMD	CorMedix Inc.	434,132	$3,407,936
7	KROS	Keros Therapeutics, Inc.	265,017	$2,835,681
8	PTCT	Ptc Therapeutics, Inc.	22,000	$1,794,540

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$390,690	27,000	-48.1%	Shares	Sole	2026-08-14
2026-03-31	$553,280	52,000	-33.8%	Shares	Sole	2026-05-15
2025-12-31	$736,330	78,500	-58.3%	Shares	Sole	2026-02-17
2025-09-30	$1,417,146	188,200	0.0%	Shares	Sole	2025-11-14
2025-06-30	$634,234	188,200	+65.4%	Shares	Sole	2025-08-14
2025-03-31	$439,268	113,800	-11.4%	Shares	Sole	2025-05-15
2024-12-31	$792,228	128,400	-45.5%	Shares	Sole	2025-02-14
2024-09-30	$1,267,528	235,600	0.0%	Shares	Sole	2024-11-14
2024-06-30	$789,260	235,600	+61.5%	Shares	Sole	2024-08-14
2024-03-31	$587,977	145,900	0.0%	Shares	Sole	2024-05-15
2023-12-31	$386,635	145,900	+81.2%	Shares	Sole	2024-02-14
2023-09-30	$189,980	80,500	—	Shares	Sole	2023-11-14
No filing history on record for this holder in this stock.